selective estrogen receptor modulator
Preliminary studies of a new selective estrogen receptor modulator (SERM 2),       raloxifene, developed for the prevention of osteoporosis, have shown that the       breast cancer rate was reduced by more than 50% without any concomitant increase        in endometrial cancer.
Preliminary studies of a new  @SUBJECT$  (SERM 2),       raloxifene, developed for the prevention of osteoporosis, have shown that the       breast cancer rate was reduced by more than 50% without any concomitant  @PREDICAT$         in  @OBJECT$ .